Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach.

Abstract

Gastroesophageal cancers (such as esophageal, gastric and gastroesophageal-junction -GEJ- lesions) are worldwide a leading cause of death being relatively rare but highly aggressive. In the past years, a clear shift in the location of upper gastrointestinal tract tumors has been recorded, both affecting the scientific research and the modern clinical practice. The integration of pre- or peri-operative multimodal approaches, as radiotherapy and chemotherapy (often combined), seems promising to further improve clinical outcome for such presentations. In the past, the definition of GEJ led to controversies and confusion: GEJ tumors have been managed either grouped to gastric or esophageal lesions, following slightly different surgical, radiotherapeutic and systemic approaches. Recently, the American Joint Committee on Cancer (AJCC) changed the staging and classification system of GEJ to harmonize some staging issues for esophageal and gastric cancer. This review discusses the most relevant historical and recent evidences of neoadjuvant treatment involving Radiotherapy for GEJ tumors, and describes the efficacy of such treatment in the frame of multimodal integrated therapies, from the new point of view of the recent classification of such tumors.

• Authors: Francesco Cellini, Alessio G Morganti, Francesco M Di Matteo, Gian Carlo Mattiucci, Vincenzo Valentini
• Journal: Radiation oncology (London, England) (Radiat Oncol) Vol. 9 Pg. 45 (Feb 05 2014) ISSN: 1748-717X [Electronic] England
• PMID: 24499595 (Publication Type: Journal Article, Review)

Topics

• Adenocarcinoma (pathology, therapy)
• Esophageal Neoplasms (pathology, therapy)
• Esophagogastric Junction (pathology)
• Evidence-Based Practice
• Humans
• Interdisciplinary Communication
• Patient Care Team
• Radiotherapy (statistics & numerical data)
• Stomach Neoplasms (pathology, therapy)